Rules and Regulations. Notice of renewal of the charter of the Advisory Committee on the Medical Uses of Isotopes
/register/2020/03/04/2020-04408·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Agency: Nuclear Regulatory Commission
Action: Notice of renewal of the charter of the Advisory Committee on the Medical Uses of Isotopes
Citation: FR Doc. 2020-04408
Summary
The U.S. Nuclear Regulatory Commission (NRC) has determined that renewal of the charter for the Advisory Committee on the Medical Uses of Isotopes (ACMUI) until February 28, 2022, is in the public interest in connection with duties imposed on the Commission by law. This action is being taken in accordance with the Federal Advisory Committee Act, after consultation with the Committee Management Secretariat, General Services Administration. The purpose of the ACMUI is to provide advice to the NRC on policy and technical issues that arise in regulating the medical use of byproduct material for diagnosis and therapy. Responsibilities include providing guidance and comments on current and proposed NRC regulations and regulatory guidance concerning medical use; evaluating certain non-routine uses of byproduct material for medical use; and evaluating training and experience of proposed authorized users. The members are involved in preliminary discussions of major issues in determining the need for changes in NRC policy and regulation to ensure the continued safe use of byproduct material. Each member provides technical assistance in his/her specific area(s) of expertise, particularly with respect to emerging technologies. Members also provide guidance as to NRC's role in relation to the responsibilities of other Federal agencies as well as of various professional organizations and boards. Members of this Committee have demonstrated professional qualifications and expertise in both scientific and non-scientific disciplines including nuclear medicine; nuclear cardiology; radiation therapy; medical physics; nuclear pharmacy; State medical regulation; patient's rights and care; health care administration; and Food and Drug Administration regulation. Contact Information: Kellee Jamerson, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555; Telephone: (301) 415-7408 or at . Dated: February 28, 2020. Russell E. Chazell, Federal Advisory Committee Management Officer. [FR Doc. 2020-04408 Filed 3-3-20; 8:45 am]